Figure 3.
(a, b) Kaplan–Meier estimates of the impact of NER on progression-free survival and overall survival after start of VEGFR-tyrosine kinase inhibitors.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.